Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
Xencor, Inc.
PharmaMar
Exelixis
EpicentRx, Inc.
Eli Lilly and Company
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Xencor, Inc.
MacroGenics
Gilead Sciences
Abramson Cancer Center at Penn Medicine
Canadian Cancer Trials Group
City of Hope Medical Center
Swiss Cancer Institute
University of Washington
Pfizer
University of Washington
Wake Forest University Health Sciences
Dana-Farber Cancer Institute
University of Southern California
NewVac LLC
University of Arizona
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
University of California, San Francisco
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
Roswell Park Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
University of Utah
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Scripps Health